A 2025 systematic review published on PubMed evaluated the clinical evidence surrounding allogeneic mesenchymal stromal cell (MSC) injections as a treatment for knee osteoarthritis (OA). The review included 11 clinical trials and offers a comprehensive overview of how MSC-based biologic therapy performs in terms of safety, efficacy, and functional outcomes.

Click here to check out the article: http://systematicreviewPubMed

Across the studies, MSC injections consistently demonstrated a favorable safety profile, with no major adverse events linked to the treatment. This reliability positions allogeneic MSCs as a well-tolerated option for patients who may not be candidates for more invasive interventions.

In terms of effectiveness, the findings are encouraging:

• Patients experienced clinically significant pain reduction, often lasting 6 to 24 months after treatment.

• Improvements in function, mobility, and quality of life were observed across multiple trials.

• Several studies also reported positive structural changes, including signs of cartilage improvement on imaging, suggesting potential regenerative benefits.

Overall, the review highlights MSC injections as a promising joint-preservation strategy within the broader field of orthoregeneration. While more large-scale, standardized trials are still needed, current evidence supports the growing role of MSC-based biologics as a safe and potentially effective treatment pathway for knee OA.